Get started
Author

Josh Bilson

Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease
2020 · Eleonora Scorletti, Paul R. Afolabi, et al. · Gastroenterology · 236
PDF
Steatotic liver disease, MASLD and risk of chronic kidney disease
2023 · Josh Bilson, Alessandro Mantovani, et al. · Diabetes & Metabolism · 168
Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis
2024 · Alessandro Mantovani, Alessandro Csermely, et al. · Gut · 46
Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function
2021 · Josh Bilson, Jaswinder K. Sethi, et al. · Proceedings of The Nutrition Society · 36
PDF
Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD
2021 · Josh Bilson, Eleonora Scorletti, et al. · Nutrition and Diabetes · 32
PDF
Impact of metabolic dysfunction severity in steatotic liver disease and its interaction with liver fibrosis on all-cause mortality and multiple hepatic and extra-hepatic outcomes
2025 · Daniel J. Cuthbertson, Oliver J. Kennedy, et al. · Metabolism · 25
Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD : A UK Biobank Study
2024 · Josh Bilson, Theresa J. Hydes, et al. · Liver International · 23
PDF
Bile Acids as Emerging Players at the Intersection of Steatotic Liver Disease and Cardiovascular Diseases
2024 · Josh Bilson, Eleonora Scorletti, et al. · Biomolecules · 17
Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD
2023 · Josh Bilson, Carolina J. Oquendo, et al. · Metabolism · 16
PDF
Heterogeneity of white adipocytes in metabolic disease
2023 · Josh Bilson, Jaswinder K. Sethi, et al. · Current Opinion in Clinical Nutrition & Metabolic Care · 11
MASLD prevalence, incidence and global aspects
2026 · Sarah H. Wild, Jeffrey V. Lazarus, et al. · Diabetologia · 6
PDF
Lipid droplets in steatotic liver disease
2023 · Josh Bilson, Eleonora Scorletti · Current Opinion in Clinical Nutrition & Metabolic Care · 6
Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults
2026 · Tina Reinson, Josh Bilson, et al. · BMJ Medicine · 5
PDF
Elevated plasma hepcidin concentrations are associated with an increased risk of mortality and nonfatal cardiovascular events in patients with type 2 diabetes: a prospective study
2024 · Alessandro Mantovani, Fabiana Busti, et al. · Cardiovascular Diabetology · 5
PDF
Genetics of MASLD: a diabetes perspective
2026 · Josh Bilson, Hanieh Yaghootkar · Diabetologia · 4
PDF
Screening to identify people with type 2 diabetes at risk of liver cancer in primary care: a randomised controlled trial protocol
2025 · Ryan M Buchanan, Tina Reinson, et al. · BMJ Open · 4
PDF
Evolving models of care in patients with metabolic dysfunction-associated steatotic liver disease, recognising its population burden and the impact of metabolic dysfunction on incident rates of hepatic and extrahepatic outcomes
2025 · Josh Bilson, Daniel J. Cuthbertson, et al. · Metabolism and Target Organ Damage · 3
PDF
Fatty liver disease and risk of all cause and cause-specific mortality outcomes in the older population
2023 · Josh Bilson, Christopher D. Byrne · HepatoBiliary Surgery and Nutrition · 2
PDF
OS-030 A multicentre randomised controlled trial of screening for MASLD in patients with type 2 diabetes not known to have liver disease in primary care
2026 · Ryan Buchanan, Tina Reinson, et al. · Journal of Hepatology · 1
Liver fat accumulation within the ‘normal range’ is associated with the presence of metabolic syndrome traits
2025 · Emily Brown, Josh Bilson, et al. · Diabetes Research and Clinical Practice · 1
Metabolic dysfunction-associated Steatotic liver disease prevalence, incidence and global aspects
2026 · Wild, Sarah H., Lazarus, Jeffrey V., et al. · ePrints Soton (University of Southampton)
P1 Testing the accuracy of FIB-4 as a rule-out test for significant liver fibrosis in people with type 2 diabetes: a multinational cross-sectional study in primary care and specialist diabetes clinics
2026 · Josh Bilson, Ryan Buchanan, et al.
PDF
O5 A multi-centre randomised controlled trial with nested cost-effectiveness evaluation ofscreening for liver disease in people living with type 2 diabetes in primary caref
2026 · Ryan Buchanan, Tina Reinson, et al.
PDF
Problems with FIB-4 as an initial screening tool for liver fibrosis in patients with type 2 diabetes
2026 · Josh Bilson, Ryan M. Buchanan, et al. · Metabolism and Target Organ Damage
PDF
Mixed acid fermentation products from Lachnospira eligens counteract myotube atrophy
2026 · Sophie Lecop, Edwige Piron, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Works count: 28
Citation count: 647
H-index: 10
I10-index: 10
Year
Topic
Type